Ruben D. Carrasco
- Hematology top 0.5%
- Multiple Myeloma Research and Treatments 27
- Oncology top 2%
- Peptidase Inhibition and Analysis 6
- Immunology top 5%
- Immunotherapy and Immune Responses 8
- Cancer Research top 5%
- Molecular Biology top 5%
- Ubiquitin and proteasome pathways 13
- Protein Degradation and Inhibitors 11
- Glycosylation and Glycoproteins Research 6
- Histone Deacetylase Inhibitors Research 6
-
- Chronic Lymphocytic Leukemia Research 13
- Co-authors
- Kenneth C. AndersonNikhil C. MunshiPaul G. RichardsonTeru HideshimaDharminder ChauhanAnthony LetaiYu‐Tzu TaiNoopur Raje
- Cited by
- HematologyOncologyImmunology
- Partner nations
- United StatesPolandItaly
In The Last Decade
Ruben D. Carrasco
60 papers receiving 3.8k citations
Hit Papers
Peers
Comparison fields: 5 of 106
- Hematology 1.2k
- Oncology 1.3k
- Immunology 889
- Cancer Research 568
- Molecular Biology 2.4k
Countries citing papers authored by Ruben D. Carrasco
This map shows the geographic impact of Ruben D. Carrasco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruben D. Carrasco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruben D. Carrasco more than expected).
Fields of papers citing papers by Ruben D. Carrasco
This network shows the impact of papers produced by Ruben D. Carrasco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruben D. Carrasco. The network helps show where Ruben D. Carrasco may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ruben D. Carrasco, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2023 | 32 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 0 | |
| 5 | 2022 | 26 | |
| 6 | 2021 | 92 | |
| 7 | 2021 | 12 | |
| 8 | 2020 | 1 | |
| 9 | 2017 | 83 | |
| 10 | Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophagesbreakdown → | 2017 | 432 |
| 11 | 2016 | 75 | |
| 12 | 2015 | 72 | |
| 13 | 2014 | 159 | |
| 14 | 2013 | 12 | |
| 15 | 2012 | 66 | |
| 16 | 2012 | 266 | |
| 17 | 2011 | 37 | |
| 18 | CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells (Blood (2009) 113, 18, (4309-4318)) | 2010 | 5 |
| 19 | 2009 | 13 | |
| 20 | 2006 | 13 |
About Ruben D. Carrasco
Ruben D. Carrasco is a scholar working on Hematology, Genetics and Immunology, having authored 64 papers that have together received 3.8k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (27 papers), Chronic Lymphocytic Leukemia Research (13 papers), Ubiquitin and proteasome pathways (13 papers), Protein Degradation and Inhibitors (11 papers), Immunotherapy and Immune Responses (8 papers), Glycosylation and Glycoproteins Research (6 papers), Peptidase Inhibition and Analysis (6 papers) and Histone Deacetylase Inhibitors Research (6 papers). The work is most often cited by research in Hematology (1.2k citations), Oncology (1.3k citations) and Immunology (889 citations). Ruben D. Carrasco has collaborated with scholars based in United States, Poland and Italy. Frequent co-authors include Kenneth C. Anderson, Nikhil C. Munshi, Paul G. Richardson, Teru Hideshima, Dharminder Chauhan, Anthony Letai, Yu‐Tzu Tai, Noopur Raje, Klaus Podar and Yiguo Hu. Their work appears in journals such as Nature, Cell and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.